CTLA4 and melanoma: Our results suggest that high plasma CD27s levels predict poorer efficacy of anti-PD1 monotherapy in melanoma but not for the combination therapy, supporting the need for therapeutic escalation with the anti-PD1 and anti-CTLA4 combination or other combination (anti-Lag3).